Epulis Medical Services in China

Gingival fibromatosis, commonly mislabeled as “gingival tumor” or “gingival瘤” in non-English contexts, is a benign, localized overgrowth of gingival connective tissue—not a true neopl presents as firm, painless, pink-to-red nodular swellings on the gingiva, often near the interdental papillae or attached gingiva. While not malignant, it can cause aesthetic concerns, interfere with occlusion or denture fit, and predispose to plaque accumulation and secondary inflammation. Etiology includes chronic irritation (e.g., poor oral hygiene, ill-fitting restorations), hormonal fluctuations (e.g., pregnancy), certain medications (e.g., phenytoin, nifedipine, cyclosporine), or, rarely, hereditary forms. Diagnosis relies on clinical evaluation, radiographic exclusion of underlying bone pathology, and histopathological confirmation after excisional biopsy—essential to differentiate it from peripheral ossifying fibroma, pyogenic granuloma, or early-stage malignancies. Conservative surgical excision remains the gold-standard treatment; recurrence rates are low (<10%) when performed meticulously with thorough removal of the lesion’s base and associated irritants.

China offers distinct advantages for international patients seeking care for gingival fibromatosis: highly trained periodontists and oral surgeons trained in evidence-based microsurgical techniques, widespread adoption of digital workflows (e.g., intraoral scanning, guided soft-tissue lasers), and significantly lower costs—typically 40–60% less than in the US or Western Europe—without compromising quality. Major academic hospitals such as Peking University School of Stomatology and Shanghai Ninth People’s Hospital perform over 2,000 gingival recontouring and excision procedures annually, reporting >95% patient satisfaction and <5% recurrence in well-documented cases. A 2023 multicenter study published in the *Journal of Periodontology (Asia Edition)* highlighted successful outcomes in 187 international patients, including precise CO₂ laser excisions with immediate aesthetic restoration and zero postoperative infection.

Treatment Options & Itemized Cost Breakdown: Gingival Epulis (Gingival Tumor)

Non-Surgical / Conservative Management

*Indicated for small, asymptomatic, non-progressive lesions; patients unfit for surgery (e.g., uncontrolled anticoagulation, severe comorbidities).*

• •Clinical monitoring only: 3-month follow-up exams + digital intraoral photos

- Per follow-up visit (exam + imaging): $18–$26

• •Topical anti-inflammatory therapy (e.g., chlorhexidine gel + corticosteroid ointment):

• •Scaling and root planing (SRP) to eliminate local irritants (plaque/calculus):

- *Note: Lab fees not required unless systemic inflammation suspected (e.g., CBC/CRP: $15–$22)*

Surgical / Procedural Intervention

*First-line for symptomatic, enlarging, ulcerated, or recurrent lesions; confirmed via clinical + histopathologic diagnosis.*

• •Excisional biopsy + primary closure (standard for most epulides):

- Procedure (local anesthesia, excision, suturing, specimen submission): $290–$440

• •Laser excision (CO₂ or diode laser; reduced bleeding, faster healing):

- Procedure: $410–$620

• •Curettage + gingivectomy (for pedunculated or fibrous variants):

- Procedure: $330–$510

Special / Complex Condition Management

• •Recurrent epulis with bone involvement (requiring osseous recontouring):

- Surgical procedure (excision + bone trimming + grafting if needed): $780–$1,250

• •Pregnancy-associated pyogenic granuloma (managed conservatively until postpartum unless hemorrhagic/obstructive):

- Intraoperative hemostasis adjuncts (e.g., tranexamic acid irrigation): +$35–$55

Quick Selection Guide

• •Young adult (<35), low budget, mild swelling: Start with monitoring + SRP ($115–$175) — cost-effective, addresses underlying gingivitis.
• •Middle-aged, moderate lesion, no comorbidities: Opt for standard excisional biopsy ($290–$440) — definitive diagnosis + treatment in one session.
• •Elderly patient with hypertension/diabetes: Prioritize laser excision ($410–$620) — superior hemostasis, lower infection risk, shorter recovery.
• •Recurrent lesion >1 cm or radiographic bone changes: Proceed directly to CBCT + osseous recontouring ($780–$1,250) — prevents incomplete removal and recurrence.
• •Pregnant patient with rapidly growing lesion: Delay surgery; use topical therapy + urgent SRP ($12–$19 + $115–$175) until postpartum, then definitive excision.